Research programme: tetracycline antimalarials - Paratek

Drug Profile

Research programme: tetracycline antimalarials - Paratek

Alternative Names: Antimalarials research programme - Paratek/MMV; Tetracycline antimalarials research programme - Paratek/University of California at San Francisco; Tetracycline antimalarials research programme - Paratek/USCF

Latest Information Update: 06 May 2015

Price : $50

At a glance

  • Originator Paratek Pharmaceuticals
  • Class Tetracyclines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 17 Sep 2010 No development reported - Preclinical for Malaria (Prevention) in USA (PO)
  • 17 Sep 2010 No development reported - Preclinical for Malaria in USA (PO)
  • 17 Sep 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top